As a brand-name drug, Zepbound often falls somewhere in the middle, so theres a chance that youll still need to pay something, even with insurance coverage
The real question is which technologies, mechanisms, pipelines, and companies will lead the next phase
In 2017, Novo Nordisk published the results of an important clinical trial, saying that Semaglutide had achieved remarkable results in the treatment of type 2 diabetes
doi:10.1056/NEJMoa2032183 Lincoff AM, BrownFrandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, HardtLindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torne CW, Ryan DH
Andrea Castagnetti, orcid.org/0000-0001-8131-974X
23 In clinical trials, treatment-discontinuation rates are around 5% to 10%